Indicated to reduce the incidence of breast cancer in women at high risk for breast cancer; high risk is defined as women aged ≥35 years with a 5-year predicted risk of breast cancer ≥1.67% (calculated by the Gail Model) 20 mg PO q Day for 5 years Data are limited for use Hypersensitivity Pregnancy Undiagnosed vaginal bleeding Patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if indication for treatment is either reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS Liver cancer and changes in liver enzyme levels reported with use; on rare occasions, a spectrum of more severe liver abnormalities including fatty liver, cholestasis, hepatitis and hepatic necrosis, that have included fatalities, also reported; monitor liver function periodically Unknown whether an increased risk for other (non-uterine) cancers is associated with tamoxifen Hypercalcemia reported in some breast cancer patients with bone metastases within a few weeks of starting treatment; if hypercalcemia occurs, treat as appropriate; if hypercalcemia is severe, discontinue therapy CYP2D6 polymorphism-CYP2D6 converts tamoxifen to active metabolite endoxifen; lowered CYP2D6 activity or concomitant CYP2D6 inhibitors may reduce tamoxifen efficacy Decreases in platelet counts, usually to 50,000-100,000/mm3, infrequently lower, reported in patients receiving therapy for breast cancer; hemorrhagic episodes have occurred, but not certain if episodes were due to tamoxifen therapy; leukopenia, sometimes in association with anemia and/or thrombocytopenia reported; neutropenia and pancytopenia also reported; perform periodic complete blood counts, including platelet counts Ocular disturbances, including corneal changes, decrement in color vision perception, retinal vein thrombosis, and retinopathy reported; an increased incidence of cataracts and need for cataract surgery reported; patients should seek medical attention if they experience visual disturbance There is increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy; when tamoxifen is coadministered with chemotherapy, there is further increase in risk of thromboembolic events; for treatment of breast cancer, carefully consider risks and benefits of tamoxifen in women with a history of thromboembolic events; advise patients to seek medical attention immediately if signs or symptoms of a thromboembolic event occur Increased incidence of uterine malignancies (endometrial adenocarcinoma and uterine sarcoma), including fatal cases, reported with treatment; underlying mechanism unknown, most uterine malignancies seen with tamoxifen are classified as adenocarcinoma of the endometrium; however, uterine sarcomas, including malignant mixed mullerian tumors (MMMT), generally associated with a higher FIGO stage (III/IV), also reported; uterine sarcoma at diagnosis usually associated with poor prognosis, and short survival; uterine sarcoma reported to occur more frequently among long-term users (≥2 years) of tamoxifen than non-users; promptly evaluate patient receiving or who has previously received therapy who reports abnormal vaginal bleeding; patients receiving or who have previously received tamoxifen should have annual gynecological examinations Therapy can cause fetal harm when administered to pregnant woman; there are postmarketing reports of vaginal bleeding, spontaneous abortions, birth defects, and fetal deaths in pregnant women taking tamoxifen; in primate model, administration of drug at doses 2 times maximum recommended human dose resulted in spontaneous abortion; advise pregnant women of potential risks to a fetus, including potential long-term risk of a DES-like syndrome; advise females of reproductive potential to use effective non-hormonal contraception during treatment with tamoxifen and for 9 months following the last dose Fetal harm may occur when administered to a pregnant woman There are postmarketing reports of vaginal bleeding, spontaneous abortions, birth defects, and fetal deaths in pregnant women taking tamoxifen In a primate model, administration of tamoxifen at doses 2 times the maximum recommended human dose resulted in spontaneous abortion Advise pregnant women of potential risks to a fetus, including potential long term risk of a DES-like syndrome Prior to initiating treatment, a negative pregnancy test should be confirmed Tamoxifen reported to inhibit lactation Two placebo-controlled studies in over 150 women have shown that tamoxifen significantly inhibits early postpartum milk production; both studies tamoxifen was administered within 24 hr of delivery for between 5 and 18 days; effect of tamoxifen on established milk production is not known There are no data that address whether tamoxifen is excreted into human milk; direct neonatal exposure of tamoxifen to mice and rats (not via breast milk) produced 1) reproductive tract lesions in female rodents (similar to those seen in humans after intrauterine exposure to diethylstilbestrol) and 2) functional defects of the reproductive tract in male rodents such as testicular atrophy and arrest of spermatogenesis Unknown if tamoxifen is excreted in human milk Because of potential for serious adverse reactions in nursing infants from tamoxifen, women taking tamoxifen should not breast feed Selective estrogen receptor modulator: nonsteroid with potent antiestrogenic effects in breast (but may be estrogen agonist in uterus); has cytostatic effect rather than cytocidal effects (cells accumulate in Go and G1 phase of the cell cycle) Half-Life: 7-14 hr Peak Plasma Time: 3-6 hr Protein binding: 99% Peak Plasma Concentration: 40 ng/m L Metabolism: by hepatic P450 enzyme CYP2C9, CYP2D6, CYP3A4 Metabolites: N-desmethyl tamoxifen, endoxifen Excretion: Feces (65%), urine (9%) Metabolized via CYP2D6 into endoxifen (4-OH-N-desmethyl-tamoxifen), its primary active metabolite Lowered CYP2D6 activity or concomitant CYP2D6 inhibitors may reduce tamoxifen efficacy Poor CYP2D6 metabolizers are defined as those with *4/*4 alleles On October 18, 2006, the Pharmaceutical Science Clinical Pharmacology Subcommittee of the FDA recommended including information on CYP2D6 genotypes and their potential effect on patient outcomes in the label for tamoxifen, but they did not come to consensus on whether testing should be recommended or considered optional Subsequent to that recommendation, branded tamoxifen (Nolvadex) was discontinued and no further guidance was given by FDA on whether to amend the label for generic tamoxifen Recent data presented at the 2010 San Antonio Breast Cancer Symposium found the CYP2D6 allele status had no effect on any outcomes, including disease recurrence, distant recurrence, and overall survival Further research will help elucidate the potential effect of strong CYP2D6 inhibitors, such as SSRIs, on tamoxifen metabolism, but there is no evidence to suggest that the use of such medications should influence the use of tamoxifen Therefore, based on the data available to date, routine testing for CYP2D6 variants is not recommended CYP2C19 heterozygous *2 carriership may be a predictive factor for patients with breast cancer using tamoxifen; this factor was associated with a longer survival among tamoxifen users in a recent study (Pharmacogenomics. 2010;11:1367-75) The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. Tamoxifen blocks the actions of estrogen, a female hormone. Certain types of breast cancer require estrogen to grow. Tamoxifen is used to treat some types of breast cancer in men and women. It is also used to lower a woman's chance of developing breast cancer if she has a high risk (such as a family history of breast cancer). Use a barrier form of birth control (such as a condom or diaphragm with spermicide) while you are using this medication and for at least 2 months after your treatment ends. Tamoxifen may also be used for purposes not listed in this medication guide. You should not use tamoxifen if you are allergic to it, or if you have a history of blood clots in your veins or your lungs, or if you are also taking a blood thinner such as warfarin (Coumadin). Before using this medicine, tell your doctor if you have liver disease, high triglycerides (a type of fat in the blood), a history of cataract, or a history of stroke or blood clot. Also tell your doctor if you if you are receiving chemotherapy or radiation treatment. Clonidine gel Do you need a prescription to purchase viagra Gardasil 0.5mg Injection is an Anti-cancer. This drug is for prevention of types of HPV that can lead to 70% of cervical cancer cases, 70% of vaginal as well up to 50. WebMD provides common contraindications for Tamoxifen Oral. Find out what health conditions may be a health risk when taken with Tamoxifen Oral Tamoxifen is contraindicated with warfarin therapy if the indication for tamoxifen is reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click In order for us to create your customized Health Savvy programs, we need a little more information about the health topic(s) that you are interested in. Press "Continue" button below to begin selecting your Health Savvy topic(s). Remember, you need at least one selected topic to use Health Savvy. If you choose this option, it cannot be undone, and you'll need to choose at least new topic to continue using your Health Savvy programs. Are you still sure that you want to clear all of you selected topics? Tamoxifen is used as a preventive treatment in people who are at high risk for developing breast cancer. Tamoxifen is also used to prevent complication in women who have had ductal carcinoma in situ (DCIS). Tamoxifen is sometimes prescribed to treat ovulation problems in women who want to get pregnant but are unable to produce eggs. In addition, the medication can be used in the treatment of Mc Cune-Albright syndrome, a genetic disease that affects the bones and color (pigmentation) of the skin in children. In addition, taking other medications as well as the severity of the cancer can play a role in the choice of the treatment. Having this information, your oncologist will recommend you an effective dosage able to combat the 20 to 40 mg in single or multiple doses, before, with or after meals. In the case of adjuvant therapy, the recommended dose is 20 mg per day, for a period of 5 years. Tamoxifen indication Tamoxifen Drug Information -, Contraindications for Tamoxifen Oral - WebMD Buy viagra sydney australiaPrednisone nursing implicationsWhere can i buy generic lexaproBuy cialis using paypalBuy synthroid 112 mcg Com Com. Tamoxifen Citrate tamoxifen citrate dose, indications.. Hormone Therapy for Breast Cancer Fact Sheet -. Tampering - Translation to Spanish, pronunciation, and forum discussions The corresponding reduction in mortality was 6% NS. The effects of about 5 years of Tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective. Brisdelle® paroxetine is a non-hormonal medication indicated for the treatment of hot flashes in menopause. Read the full Prescribing Information, including Boxed.